

5. (Amended) A prokaryotic or eukaryotic expression vector [characterized in that it includes] wherein it comprises the recombinant nucleotide sequence of [any of claims 1 or 4] claim 1, and in that it is able to express the biologically active metallo-carboxypeptidase inhibitor.

6. (Amended) A transformed *Escherichia coli* cell [characterized in that] wherein it comprises an expression vector according to claim 5 and in that it is able to produce the biologically active metallo-carboxypeptidase inhibitor.

7. (Amended) A procedure to prepare a recombinant metallo-carboxypeptidase inhibitor identified as SEQ ID 2 according to [any of claims 2 to 3 characterized in that] claim 2, wherein it comprises

(i) the culture of the transformant that contains an expression vector capable of expressing a biologically active metallo-carboxypeptidase inhibitor; and

(ii) its obtention and purification.

8. (Amended) A procedure according to claim 7 [characterized in that] wherein the recombinant process takes place in a prokaryotic or eukaryotic host.

9. (Amended) A metallo-carboxypeptidase inhibitor according to [claims 2 or 3] claim 2, as fibrinolytic agent.

10. (Amended) Use of the metallocarboxypeptidase inhibitor according to [claims 2 or 3] claim 2, to prepare a drug useful as fibrinolytic agent.

Please add the following new claims.

13. (New) A prokaryotic or eukaryotic expression vector wherein it comprises the recombinant nucleotide sequence of claim 2, and in that it is able to express the biologically active metallocarboxypeptidase inhibitor.

14. (New) A prokaryotic or eukaryotic expression vector wherein it comprises the recombinant nucleotide sequence of claim 3, and in that it is able to express the biologically active metallocarboxypeptidase inhibitor.

15. (New) A prokaryotic or eukaryotic expression vector wherein it comprises the recombinant nucleotide sequence of claim 4, and in that it is able to express the biologically active metallocarboxypeptidase inhibitor.

16. (New) A procedure to prepare a recombinant metallocarboxypeptidase inhibitor identified as SEQ ID 2 according to claim 3, wherein it comprises

(i) the culture of the transformant that contains an expression vector capable of expressing a biologically active metallocarboxypeptidase inhibitor; and

(ii) its obtention and purification.

17. (New) A metalloproteinase inhibitor according to claim 3, as fibrinolytic agent.
18. (New) Use of the metalloproteinase inhibitor according to claim 3, to prepare a drug useful as fibrinolytic agent.

Enclosed please find an “Un-Marked Version of the Claims as Amended” including all of the amendments made to the claims above. Please note, additions to the claims are denoted by underlining and deletions from the claims are denoted by bracketing. In addition, the “Un-Marked Version of the Claims as Amended” contain new claims 13-18 added herein.

#### REMARKS

It is respectfully requested that the amendments to the claims made under Rule 26 of Article 34, in response to the International Preliminary Examination Report, be entered for purposes of the present application.

Claims 1-18 are presently active, claims 13-18 having been added herein. It is respectfully submitted that new claims 13-18 are commensurate in scope with the subject matter of original claims 5, 7, 9 and 10.

The amendments to the claims herein have been made to conform the claims to U.S. practice and have not been made for purposes of patentability. In addition, the claims have been amended to remove multiple dependencies therefrom in order to reduce the filing fee and to more